Journal of Guangxi Normal University(Natural Science Edition) ›› 2022, Vol. 40 ›› Issue (2): 191-199.doi: 10.16088/j.issn.1001-6600.2021022202
Previous Articles Next Articles
ZHOU Jun1,2,3, CHEN Shuman1,2,3, XING Bing1, CHEN Yajing1,2,3, LI Yinling1,2,3, HE Liu1,2,3, ZHOU Zuping1,2,3, PU Shiming1,2,3*
CLC Number:
| [1] ROMASZKO A M, DOBOSZYN′SKA A. Multiple primary lung cancer: A literature review[J]. Advances in Clinical and Experimental Medicine, 2018, 27(5): 725-730. DOI: 10.17219/acem/68631. [2] NASIM F, SABATH B F, EAPEN G A. Lung cancer[J]. The Medical Clinics of North America, 2019, 103(3): 463-473. DOI: 10.1016/j.mcna.2018.12.006. [3] MAO Y S, YANG D, HE J, et al. Epidemiology of lung cancer[J]. Surgical Oncology Clinics of North America, 2016, 25(3): 439-445. DOI: 10.1016/j.soc.2016.02.001. [4] RODRIGUEZ-CANALES J, PARRA-CUENTAS E, WISTUBA I I. Diagnosis and molecular classification of lung cancer[J]. Cancer Treatment and Research, 2016, 170: 25-46. DOI: 10.1007/978-3-319-40389-2_2. [5] WU T, DAI Y. Tumor microenvironment and therapeuticresponse[J]. Cancer Letters, 2017, 387: 61-68. DOI: 10.1016/j.canlet.2016.01.043. [6] ARNETH B. Tumor Microenvironment[J]. Medicina, 2019, 56(1): 15. DOI: 10.3390/medicina56010015. [7] GALDIERO M R, BONAVITA E, BARAJON I, et al. Tumor associated macrophages and neutrophils in cancer[J]. Immunobiology, 2013, 218(11): 1402-1410. DOI: 10.1016/j.imbio.2013.06.003. [8] KALINSKI P, TALMADGE J E. Tumor immuno-environment in cancer progression and therapy[J]. Advances in Experimental Medicine and Biology, 2017, 1036: 1-18. DOI: 10.1007/978-3-319-67577-0_1. [9] CHEN X, DU Y, HUANG Z. CD4+CD25+ treg derived from hepatocellular carcinoma mice inhibits tumor immunity[J]. Immunology Letters, 2012, 148(1): 83-89. DOI: 10.1016/j.imlet.2012.09.002. [10] SOJKA D K, HUGHSON A, FOWELL D J. CTLA-4 is required byCD4+CD25+ Treg to control CD4+ T-cell lymphopenia-induced proliferation[J]. European Journal of Immunology, 2009, 39(6): 1544-1551. DOI: 10.1002/eji.200838603. [11] FUJIO K, YAMAMOTO K, OKAMURA T, et al. Overview of LAG-3-Expressing, IL-10-producing regulatory T cells[J]. Current Topics in Microbiology and Immunology, 2017, 410: 29-45. DOI: 10.1007/82_2017_59. [12] COLLISON L W, WORKMAN C J, KUO T T, et al. The inhibitory cytokine IL-35 contributes to regulatory T-cell function[J]. Nature, 2007, 450(7169): 566-569. DOI: 10.1038/nature06306. [13] LI X L, YANG A M, HUANG H, et al. Induction of type 2 T helper cell allergen tolerance by IL-10-differentiated regulatory dendritic cells[J]. American Journal of Respiratory Cell and Molecular Biology, 2010, 42(2): 190-199. DOI: 10.1165/rcmb.2009-0023OC. [14] JARNICKI A G, LYSAGHT J, TODRYK S, et al. Suppression of antitumor immunity by IL-10 and TGF-beta-producing T cells infiltrating the growing tumor: influence of tumor environment on the induction of CD4+ and CD8+ regulatory T cells[J]. Journal of Immunology, 2006, 177(2): 896-904. DOI: 10.4049/jimmunol.177.2.896. [15] VANDENBARK A A, OFFNER H. Critical evaluation of regulatory T cells in autoimmunity: are the most potent regulatory specificities being ignored?[J]. Immunology, 2008, 125(1): 1-13. DOI: 10.1111/j.1365-2567.2008.02900.x. [16] 肖捷, 杨丽萍, 肖健, 等. CD4+CD25+调节性T细胞在AIHA患者外周血中的表达及临床意义[J]. 中国医药科学, 2020, 10(16): 199-202. [17] 王宇, 周建松, 许敏. CD4+CD25+Foxp3+调节性T细胞与肺癌患者预后的关系[J]. 热带医学杂志, 2021, 21(1): 61-65. [18] WING K, SURI-PAYER E, RUDIN A. CD4+CD25+-regulatory T cells from mouse to man[J]. Scandinavian Journal of Immunology, 2005, 62(1): 1-15. DOI: 10.1111/j.1365-3083.2005.01634.x. [19] ZHANG J H, DENG J H, YAO X L, et al. CD4(+)CD25(+) tregs as dependent factor in the course of bleomycin-induced pulmonary fibrosis in mice[J]. Experimental Cell Research, 2020, 386(1): 111700. DOI: 10.1016/j.yexcr.2019.111700. [20] SHIM J, LEE E S, PARK S, et al. CD4(+)CD25(+) regulatory T cells ameliorate Behcet's disease-like symptoms in a mouse model[J]. Cytotherapy, 2011, 13(7): 835-847. DOI: 10.3109/14653249.2011.571245. [21] 周奕辰, 王金岩. CD4+CD25+Treg细胞在小鼠Lewis肺癌生长及转移中的作用[J]. 中国免疫学杂志, 2019, 35(14): 1712-1716. [22] CHAI J G. Cancer vaccination reprograms regulatory T cells into helper CD4 T cells to promote antitumor CD8 T-cell responses[J]. Immunotherapy, 2011, 3(5): 601-604. DOI: 10.2217/imt.11.22. [23] SHARMA M D, HOU D Y, BABAN B, et al. Reprogrammed Foxp3+ regulatory T cells provide essential help to support cross-presentation and CD8+ T cell priming in naive mice[J]. Immunity, 2010, 33(6): 942-954. DOI: 10.1016/j.immuni.2010.11.022. |
| [1] | LI Yinling, ZHOU Jing, CHEN Ying, CHEN Qiaoyuan, LIN Wanhua. Study on the Abnormal Expression of Sdr9c7 Gene in Erythrocytes of Tumor-bearing Mice [J]. Journal of Guangxi Normal University(Natural Science Edition), 2021, 39(6): 147-153. |
| [2] | MEI Han-bing, WANG Wei, YAO Xue, CHENG Lian-biao, HUANG Jin. Inhibitory Activity and Mechanism of Hsp90 Inhibitor Cynaroside Against Non-small Cell Lung Cancer in Vitro [J]. Journal of Guangxi Normal University(Natural Science Edition), 2015, 33(3): 91-97. |
|